Is vinclozolin a reproductive hazard to men?

Zober et al. examined fertility, hormones, and offspring sex ratio of men exposed to the fungicide vinclozolin. These authors were inclined to dismiss the possibility that it has an deleterious action on the male reproductive system. I should like to suggest in contrast, that its effects in two respects resemble those of the nematocide dibromochloropropane (DBCP), which lowers sperm count and is associated with a highly significantly lowered offspring sex ratio.1

Zober et al. report that although the testosterone concentrations of exposed men were unchanged their follicle stimulating hormone (FSH) concentrations were significantly higher than those of controls (P = 0.004). Similarly, increased FSH and unchanged testosterone were found in men exposed to DBCP.1 Increased gonadotrophin, or lowered testosterone concentrations, or both are characteristic of many illnesses in men.2

The offspring of men exposed to vinclozolin numbered 89 sons and 51 daughters. Compared with an expected Caucasian live birth sex ratio (proportion male) of 0.515, these figures yield a χ² of 1.05 (P = 0.15, one way). So although not formally significant, they may be thought to be suggestive.3 I suggest that further study of the possible effects of vinclozolin on the male reproductive system are merited. Its known similarities to an established hazard, DBCP, are disturbing. Especially interesting (and easy to gather) would be the sex ratios of offspring of men exposed to vinclozolin.

WILLIAM H JAMES
The Gatton Laboratory, University College London, Wills House, 4 Stephenson Way, London NW1 2HE


Authors reply—In his letter, James raises questions about two specific health outcome measures reported in our paper, namely, serum follicle stimulatory hormone (FSH) and sex of children born to fathers in the study group, and suggests that our findings for vinclozolin are similar to those reported by others for dibromochloropropane (DBCP), a known reproductive toxin in men.

As was pointed out by James, the mean value of the FSH measurements was significantly higher in the exposed than in the control group (P = 0.004 both before and after exclusions based on known pre-exposure health conditions) and this would suggest a possible causal relation between exposure and outcome. However, for both luteinising hormone (LH) and FSH, non-significant but negative dose-response trends were found relative to current intensity as well as estimates of cumulative dose of vinclozolin exposure (see fig 4 of original paper for scatter plot of FSH v current intensity measure). Also, the man in the exposed group whose FSH level of 14.0 mU/ml was at the upper normal unlabelled atrophy only later found to have been present since childhood. All other readings among exposed men were within the reference range. From toxicological studies on vinclozolin and studies on other agents that block the testosterone receptor such as flutamide, the pattern of gonadotrophins at effective dose rates typically consists of increased testosterone, greatly increased LH, and marginally increased FSH concentrations.1,4 In the absence of dose-response and any abnormal FSH findings within the restricted exposed group and the lack of similarity between observed gonadotrophin patterns and those would be expected for an antiandrogenic agent, it is difficult to conclude that our findings are indicative of an effect related to vinclozolin.

Because the medical histories reported in table 3 of our paper did not distinguish between births occurring before and after first exposure, we reviewed the medical and work history data of all study group participants to find the number and sex of children born nine or more months after the date of the first exposure. Within this restricted observation period, there were 31 births, 13 male and 18 female, reported by 21 members of the study group. The number of births per family was considerably less than one from one to three. There were eight families with more male than female children born after exposure, 11 families with more female than male children and two families with one male and one female child born after exposure. These more detailed data are consistent with the trend noted by James, but are also consistent with a chance distribution of children by sex. Again available toxicological data for vinclozolin indicate that at toxicologically effective doses, it is not the sex ratio of offspring that is affected, but rather development in males.1

A further issue raised by James was the resemblance between the effects of vinclozolin and those of DBCP on the basis of our FSH and sex ratio findings. From a toxicological viewpoint, there are few similarities between the two substances. DBCP has been shown to affect testicular tissue through direct genotoxic effects.1 Vinclozolin is not genotoxic and does not affect Sertoli cells directly, but rather acts by blocking the androgen receptors.3 This mechanism of action is quite different from that of DBCP and the anticipated pattern of gonadotrophin findings and their implications would be expected to be different as well.

In conclusion, we do concur with the suggestion that further systematic observation of people likely to have contact with vinclozolin is prudent and would be of scientific merit. However, we do not agree with the analogy drawn between vinclozolin and DBCP, which is not, in our opinion, supported by existing toxicological and epidemiological data.

A ZOBER
B VAN RAVENZWAAY

1 van Ravenzwaay B. Discussion of prenatal and reproductive toxicity of vinclozolin (3,3-dichloro-1,1-dimethylurea). Data submission to US EPA. Washington: BASF Corporation MRID, 1991. (No. 42593-12-03.)

Modifiers of non-specific symptoms in occupational and environmental syndromes

Editor—In a thorough review Spurgeon et al. concluded that various occupational or environmental factors may lead to an increase of non-specific symptoms such as headache, tiredness, eye irritation, and backache when they are (repeatedly) perceived as health hazards. Dissatisfaction with specific aspects of work may stimulate the occurrence of a similar pattern of health complaints. The authors discussed the role of individual and social factors in the perception of health and the tendency to report symptoms. Most probably some people are more sensitive to the psychosocial factors mentioned.

Spurgeon et al. did not pay attention to one point. If anxiety and dissatisfaction affect the perception of health, there might be a comparable effect on the perception of environmental factors. If so, negative or anxious feelings may also intensify the reporting of complaints about aspects of work in a non-specific way.

Many studies in the field of occupational epidemiology are at (least partly) based on self-reported health or work related exposures. It is obvious that the tendencies mentioned may lead to biased results. Any particular problem that crops up in a work situation may generate and sustain dissatisfaction, which in turn stimulates the tendency to report non-specific symptoms and complaints. Assuming that this tendency is stronger in some people than others, spurious associations between work and health effect can be expected. This is an additional reason to explore how psychosocial factors may colour the reporting of complaints.1 Two topics should therefore be added to the recommendations for future research as formulated by Spurgeon et al.1

(1) Empirical evidence should be searched for our hypothesis that feelings of anxiety or dissatisfaction may intensify the reporting of complaints about (probably non-specific) aspects of work. Research done on
Is vinclozolin a reproductive hazard to men?

W H James

*Occup Environ Med* 1997 54: 285
doi: 10.1136/oem.54.4.285

Updated information and services can be found at:
http://oem.bmj.com/content/54/4/285.1.citation

**Email alerting service**

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/